Verastem, Inc. (VSTM)

Market Cap	293.98M
Revenue (ttm)	10.00M
Net Income (ttm)	-148.88M
Shares Out	54.95M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,823,393
Open	5.31
Previous Close	5.27
Day's Range	5.27 - 5.62
52-Week Range	2.10 - 9.10
Beta	0.71
Analysts	Strong Buy
Price Target	12.63 (+136.08%)
Earnings Date	Aug 7, 2025

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM
• Website: https://www.verastem.com

Analyst Summary

According to 9 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $12.63, which is an increase of 136.08% from the latest price.

Price Target

$12.63

(136.08% upside)

Analyst Consensus: Strong Buy